Coeptis Therapeutics

A catalyst for developing
therapies that improve
outcomes.

PartnershipsDNADevelopmentTherapeutics
Developing therapies that improve outcomes

Our Pipeline

Coeptis’ pipeline is evolving from the partnerships being created with multiple pharmaceutical companies currently. As these relationships unfold, the product pipeline will be updated accordingly.

partner with Coeptis

Partnerships

Our current business model is designed around commercializing and furthering the development of our products, as well as entering into license agreements and strategic partnerships in exciting, new therapeutic areas such as auto-immune diseases and oncology. Coeptis continually seeks partnership opportunities with companies that have novel therapies in development or companies with technologies that improve the way that drugs are delivered to patients.

hex
Investor relations

Investor Relations

Coeptis Therapeutics, Inc. (formerly Vinings Holdings, Inc.) conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. Coeptis Therapeutics’ common stock is currently quoted on the OTC PINK under the symbol “COEP.” Our Investor Relations page is for the benefit of investors in Coeptis Therapeutics.

For further updates, visit our Investor Relations page by clicking here.

ABOUT COEPTIS

Leadership

Dave Mehalick – President & CEO
Christine Sheehy – Chief Financial Officer
Dan Yerace – Vice President, Operations
Gary Conte – Senior Vice President, Sales and Marketing

Dave Mehalick – President & CEO

Christine Sheehy – Chief Financial Officer

Dan Yerace – Vice President, Operations

Gary Conte – Senior Vice President, Sales and Marketing

 

Coeptis history

History

Coeptis Therapeutics, Inc. was previously named Vinings Holdings, Inc., and became Coeptis Therapeutics by way of a name change on July 12, 2021. Coeptis Therapeutics, with its subsidiary Coeptis Pharmaceuticals, focuses on the development and/or acquisition of pharmaceutical products which offer improvements to current therapies, thereby, improving patient outcomes.

Coeptis Therapeutics, Inc. was previously named Vinings Holdings, Inc., and became Coeptis Therapeutics by way of a name change on July 12, 2021. Coeptis Therapeutics, with its subsidiary Coeptis Pharmaceuticals, focuses on the development and/or acquisition of pharmaceutical products which offer improvements to current therapies, thereby, improving patient outcomes.

CONTACT